DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

DEVELOPMENTS

3 Drugs in Development

3 Drugs in Development

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

3DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: Azd-0364, Azd0364, 2097416-76-5, Vo9kx45qiq, Chembl4482864, (6r)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one

Molecular Formula

C₂₄H₂₄F₂N₈O₂

Molecular Weight

494.5 g/mol

InChI Key

HVIGNZUDBVLTLU-MRXNPFEDSA-N

FDA UNII

VO9KX45QIQ

Tizaterkib is an orally bioavailable inhibitor of the extracellular signal-regulated kinases 1 (ERK1) and 2 (ERK2), with potential antineoplastic activity. Upon oral administration, tizaterkib specifically targets, binds to and inhibits the activity of the serine/threonine-protein kinases ERK1 and ERK2, thereby preventing the phosphorylation of ERK1/2 substrates and the activation of mitogen-activated protein kinase (MAPK)/ERK-mediated signal transduction pathways. This results in the inhibition of ERK-dependent proliferation and survival of tumor cells. The MAPK/ERK pathway, also known as the RAS/RAF/MEK/ERK pathway, is hyperactivated in a variety of tumor cell types due to mutations in upstream targets. It plays a key role in the proliferation, differentiation and survival of tumor cells.

1 2D Structure

ATG-017

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

(6R)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one

2.1.2 InChI

InChI=1S/C24H24F2N8O2/c1-14-9-27-24(30-20-6-7-28-32(20)2)31-21(14)19-12-33-11-16(13-36-3)34(23(35)22(33)29-19)10-15-4-5-17(25)18(26)8-15/h4-9,12,16H,10-11,13H2,1-3H3,(H,27,30,31)/t16-/m1/s1

2.1.3 InChI Key

HVIGNZUDBVLTLU-MRXNPFEDSA-N

2.1.4 Canonical SMILES

CC1=CN=C(N=C1C2=CN3CC(N(C(=O)C3=N2)CC4=CC(=C(C=C4)F)F)COC)NC5=CC=NN5C

2.1.5 Isomeric SMILES

CC1=CN=C(N=C1C2=CN3C[C@@H](N(C(=O)C3=N2)CC4=CC(=C(C=C4)F)F)COC)NC5=CC=NN5C

2.2 Other Identifiers

2.2.1 UNII

VO9KX45QIQ

2.3 Synonyms

2.3.1 MeSH Synonyms

1. (6r)-7-(3,4-difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1h-pyrazol-5-yl)amino)-4-pyrimidinyl)-6,7-dihydroimidazo(1,2-a)pyrazin-8(5h)-one

2. Azd-0364

3. Azd0364

4. Imidazo(1,2-a)pyrazin-8(5h)-one, 7-((3,4-difluorophenyl)methyl)-6,7-dihydro-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1h-pyrazol-5-yl)amino)-4-pyrimidinyl)-, (6r)-

2.3.2 Depositor-Supplied Synonyms

1. Azd-0364

2. Azd0364

3. 2097416-76-5

4. Vo9kx45qiq

5. Chembl4482864

6. (6r)-7-[(3,4-difluorophenyl)methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one

7. (r)-7-(3,4-difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1h-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo[1,2-a]pyrazin-8(5h)-one

8. (6~{r})-7-[[3,4-bis(fluoranyl)phenyl]methyl]-6-(methoxymethyl)-2-[5-methyl-2-[(2-methylpyrazol-3-yl)amino]pyrimidin-4-yl]-5,6-dihydroimidazo[1,2-a]pyrazin-8-one

9. (r)-7-(3,4-difluorobenzyl)-6-(methoxymethyl)-2-(5-methyl-2-((1-methyl-1h-pyrazol-5-yl)amino)pyrimidin-4-yl)-6,7-dihydroimidazo(1,2-a)pyrazin-8(5h)-one

10. Tizaterkib [inn]

11. Unii-vo9kx45qiq

12. Schembl18839079

13. Gtpl11674

14. Atg-017

15. Amy14750

16. Azd 0364

17. Bcp29508

18. Ex-a1812

19. Bdbm50505988

20. Mfcd31631580

21. Nsc808790

22. S8708

23. Akos037648851

24. Azd0364; Azd 0364

25. At10135

26. Azd0364 Pound Atg-017 Pound(c)

27. Nsc-808790

28. Ac-36188

29. Ba166426

30. Bs-15828

31. Hy-111483

32. Cs-0042190

33. Q50825500

34. Lhz

2.4 Create Date

2017-08-04

3 Chemical and Physical Properties

Molecular Formula	C₂₄H₂₄F₂N₈O₂
Molecular Weight	494.5 g/mol
XLogP3	2
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	9
Rotatable Bond Count	7
Exact Mass	494.19902836 g/mol
Monoisotopic Mass	494.19902836 g/mol
Topological Polar Surface Area	103 Å²
Heavy Atom Count	36
Formal Charge	0
Complexity	768
Isotope Atom Count	0
Defined Atom Stereocenter Count	1
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1